Publication: Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
Loading...
Files
Date
2022-03-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov)
Description
Keywords
Tıp, Sağlık Bilimleri, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji, Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases, Oncology, ONKOLOJİ, Klinik Tıp, Klinik Tıp (MED), ONCOLOGY, CLINICAL MEDICINE, Clinical Medicine (MED), cancer, chemotherapy, CoronaVac, COVID-19, COVID-19 vaccines, immunotherapy, malignancy, SARS-CoV-2
Citation
YASİN A. İ., Aydin S. G., SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli C., Ozturk A., Perkin P., Demirtas D., Erdemoglu E., et al., "Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study", FUTURE ONCOLOGY, cilt.18, ss.1235-1244, 2022